Skip to main content

Peer Review reports

From: A phase I dose-escalation study of selumetinib in combination with docetaxel or dacarbazine in patients with advanced solid tumors

Original Submission
19 Aug 2016 Submitted Original manuscript
30 Aug 2016 Author responded Author comments - Patricia M LoRusso
Resubmission - Version 2
30 Aug 2016 Submitted Manuscript version 2
23 Sep 2016 Reviewed Reviewer Report - Roberto Passera
23 Sep 2016 Reviewed Reviewer Report - Nagio Takigawa
21 Dec 2016 Author responded Author comments - Patricia M LoRusso
Resubmission - Version 3
21 Dec 2016 Submitted Manuscript version 3
12 Jan 2017 Author responded Author comments - Patricia M LoRusso
Resubmission - Version 4
12 Jan 2017 Submitted Manuscript version 4
Publishing
15 Feb 2017 Editorially accepted
6 Mar 2017 Article published 10.1186/s12885-017-3143-6

You can find further information about peer review here.

Back to article page